To include your compound in the COVID-19 Resource Center, submit it here.

Insmed jumps on Phase III success in rare lung infection

Insmed Inc. (NASDAQ:INSM) soared $14.70 (120%) to $26.99 on Tuesday and ended the day with about $1.7 billion in market cap after reporting that ALIS

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE